Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the ona domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/risezcom/public_html/cord-blood.org.uk/wp-includes/functions.php on line 6170
Advances in Eczema Treatment Using Cord Blood Cells - Cord Blood

Cord Blood

and Stem Cell Banking

Advances in Eczema Treatment Using Cord Blood Cells

A scientist looking at test tubes in a laboratory

Researchers have found a novel way to potentially soothe the itch and discomfort of eczema using cells derived from umbilical cord blood. Eczema, also known as atopic dermatitis, is more than just dry skin. It’s an inflammatory condition that can cause red, itchy patches on the skin, often in response to allergens. People with eczema may experience flare-ups when exposed to certain triggers or when their skin barrier is weakened. This can lead to discomfort and a significant impact on quality of life.

The Cord Blood Cell Breakthrough

The exciting development comes from a study led by ViGenCell, in collaboration with Professor Lee Ji-hyun from the Catholic University of Korea. Their research, published in the prestigious journal Frontiers in Immunology, showcases a new treatment method using cord blood-derived myeloid suppressor (CBMS) cells. This study is a big deal because it’s the first to show a direct therapeutic effect of these cells in treating eczema.

What Are CBMS Cells?

CBMS cells are a type of cell extracted from umbilical cord blood. What makes them special is their ability to regulate the immune system. Since eczema is partly caused by an overactive immune response, these cells could be key in managing the condition.

The Study and Its Findings

In the study, researchers used an animal model of eczema triggered by house dust mites. They treated one group with CBMS cells and compared them with a control group. The results were promising! The group treated with CBMS cells showed:

  • A significant reduction in eczema severity.
  • Improvement in skin barrier function.
  • Decreased inflammation.

These improvements were linked to the CBMS cells interacting with T cells (a type of immune cell) and boosting skin proteins essential for a healthy skin barrier.

Practical Implications

What’s truly remarkable is that these benefits were seen even with lower concentrations of cells than what’s usually used in cell therapies. This suggests that CBMS cell therapy could be an effective and efficient treatment option.

The Future of Eczema Treatment

This research is a big step forward. It not only demonstrates a potential new treatment for eczema but also helps us understand more about how to repair the skin barrier. Kim Su-eon, leader of the ViMedier Platform Group at ViGenCell, emphasises the significance of this discovery. Their team is committed to continuing research and development in this area, offering hope for new, effective treatments for eczema sufferers.